@spartacus - I noticed your comment around $3.29M (revenue) versus $3.604M (receipts from customers) and some possible confusion? The revenue represents the sales invoice figures - i.e. orders for stock placed by customers during the quarter (not necessarily paid for by the customer). In the annual report it notes the trade terms are typically 30 days from end of month. An order placed and invoiced on 15/6/2017 (say) would then give the customer until 31/7/2017 to pay and appear as a “receipt from customer” in the September quarter (assuming they pay in July).
@All - Using the revenue and and percentage gain/loss figures in recent quarterly reports it is possible to estimate the sales figures for each division as shown below -
Clements seems to have got its mojo back doing sales of around $360K in the quarter and slightly eclipsing the Q2 FY2016 result. Prior to this quarter they were doing sales in a band from roughly $280K to $310K. Great to see confirmation the Ardo breast pumps are now making a contribution to the upward climb.
OEM has dropped to a record low and is likely to fall further in the next quarter. The absolute peak was Q2 FY2017 and associated with CareFusion buying up stock as insurance ahead of finalising plans not to renew the MLA OEM contract.
Tuta is rock solid as always. Q3 FY2017 was a highlight where they matched the prior quarter’s results (traditionally a drop occurs because of holidays in January). In Q4 the upward trend has continued and surpassed $2.5M for the first time.
MLA Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
